Safe Orthopaedics SA (ALSAF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Safe Orthopaedics SA (ALSAF) has a cash flow conversion efficiency ratio of 0.098x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.53 Million ≈ $-1.79 Million USD) by net assets (€-15.70 Million ≈ $-18.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Safe Orthopaedics SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Safe Orthopaedics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALSAF liabilities breakdown for a breakdown of total debt and financial obligations.
Safe Orthopaedics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Safe Orthopaedics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Block Energy PLC
LSE:BLOE
|
0.007x |
|
Mosman Oil and Gas Ltd
LSE:MSMN
|
-0.118x |
|
Konan Technology Inc.
KQ:402030
|
N/A |
|
DSW Capital PLC
LSE:DSW
|
-0.032x |
|
Cerinnov Group SA
PA:ALPCV
|
0.999x |
|
LORDS CO. WORLDW. HOLD.
F:4XM
|
N/A |
|
IMAC Holdings Inc
NASDAQ:BACK
|
0.228x |
|
Zoo Digital Group Plc
LSE:ZOO
|
0.019x |
Annual Cash Flow Conversion Efficiency for Safe Orthopaedics SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of Safe Orthopaedics SA from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ALSAF market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-8.42 Million ≈ $-9.85 Million |
€-3.27 Million ≈ $-3.82 Million |
0.388x | +6809.83% |
| 2023-12-31 | €-202.35 Million ≈ $-236.57 Million |
€-1.14 Million ≈ $-1.33 Million |
0.006x | -99.87% |
| 2022-12-31 | €-1.28 Million ≈ $-1.50 Million |
€-5.47 Million ≈ $-6.40 Million |
4.277x | +127.20% |
| 2021-12-31 | €398.00K ≈ $465.30K |
€-6.26 Million ≈ $-7.32 Million |
-15.726x | +37.73% |
| 2020-12-31 | €237.00K ≈ $277.08K |
€-5.99 Million ≈ $-7.00 Million |
-25.253x | -2243.74% |
| 2019-12-31 | €-4.28 Million ≈ $-5.00 Million |
€-5.04 Million ≈ $-5.90 Million |
1.178x | +122.61% |
| 2018-12-31 | €1.19 Million ≈ $1.39 Million |
€-6.21 Million ≈ $-7.27 Million |
-5.210x | -11.80% |
| 2017-12-31 | €1.06 Million ≈ $1.24 Million |
€-4.93 Million ≈ $-5.76 Million |
-4.660x | +70.49% |
| 2016-12-31 | €367.00K ≈ $429.06K |
€-5.80 Million ≈ $-6.78 Million |
-15.793x | -1137.00% |
| 2015-12-31 | €5.09 Million ≈ $5.95 Million |
€-6.50 Million ≈ $-7.60 Million |
-1.277x | +37.81% |
| 2014-12-31 | €2.46 Million ≈ $2.88 Million |
€-5.05 Million ≈ $-5.91 Million |
-2.053x | -111.11% |
| 2013-12-31 | €-194.00K ≈ $-226.81K |
€-3.58 Million ≈ $-4.19 Million |
18.479x | +960.95% |
| 2012-12-31 | €1.17 Million ≈ $1.37 Million |
€-2.51 Million ≈ $-2.93 Million |
-2.146x | -- |
About Safe Orthopaedics SA
Safe Orthopaedics SA, a medical technology company, develops and markets ready-to-use implants and sterile instrumentation for spinal surgery in France. It offers SteriSpine PS, an all-round kit for open, mini open, and MIS surgeries, as well as percutaneous kit; SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems; SteriSpine LC, a ready to use instrumentation for lu… Read more